Saturday 17 October 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 58.7% and free cash flow fell 64.8%, each against the same quarter a year earlier.
27.57
2.00
−6.76%
Follow RAPP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (39.96%) | (28.33%) | (28.22%) | (23.41%) |
+8 more TTM periods Free account |
|
| (36.85%) | (26.83%) | (26.95%) | (22.55%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(32.60%) | (22.86%) | (23.11%) | (19.18%) | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(2.04) | (1.71) | (2.26) | (2.05) | |
Free Cash Flow |
(96.96) | (80.71) | (88.09) | (77.89) | |
Capital Expenditures |
(0.27) | (0.41) | (0.62) | (0.67) | |
| Other line items | |||||
Cash ROIC |
(11.29%) | (8.51%) | (9.03%) | (7.60%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.70 | 0.75 | 0.78 | 0.79 | |
Depreciation/Fixed assets |
0.03 | (0.13) | (0.13) | 0.40 | |
Capex/Depreciation |
(3.75) | 1.27 | 1.63 | (0.54) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.04) | (1.70) | (2.25) | (2.04) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates